LAST week, the US Food and Drug Administration approved a form of ketamine for use in treatment-resistant depression. This is a landmark moment. Esketamine, as it is known, is the first novel drug therapy for depression to emerge in over 50 years.
People will administer the esketamine themselves, under the supervision of a healthcare professional, by squirting it up their nose. At first they will take it a few times a week, then monthly.
Given that ketamine use can…